• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Heska Corporation

    6/13/23 11:09:23 AM ET
    $HSKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $HSKA alert in real time by email
    S-8 POS 1 brhc20054263_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on June 13, 2023

    Registration No. 333-30951
    Registration No. 333-34111
    Registration No. 333-47129
    Registration No. 333-72155
    Registration No. 333-38138
    Registration No. 333-39448
    Registration No. 333-55112
    Registration No. 333-82096
    Registration No. 333-89738
    Registration No. 333-102871
    Registration No. 333-106679
    Registration No. 333-112701
    Registration No. 333-115995
    Registration No. 333-123196
    Registration No. 333-132916
    Registration No. 333-141737
    Registration No. 333-194120
    Registration No. 333-194122
    Registration No. 333-195734
    Registration No. 333-204036
    Registration No. 333-211567
    Registration No. 333-225112
    Registration No. 333-238006
    Registration No. 333-238008
    Registration No. 333-255803
    Registration No. 333-266637

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549



    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-30951
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-34111
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-47129
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-72155
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-38138
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-39448
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-55112
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-82096
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-89738
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-102871
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-106679
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-112701
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-115995
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-123196
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-132916
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-141737
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-194120
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-194122
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-195734
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-204036
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-211567
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-225112
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-238006
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-238008
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-255803
    Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-266637

    UNDER
    THE SECURITIES ACT OF 1933


    HESKA CORPORATION
    (Exact name of registrant as specified in its charter)

    Delaware
    77-0192527
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)

    3760 Rocky Mountain Avenue
    Loveland, Colorado 80538
    (970) 493-7272
    (Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

    Heska Corporation Employee Stock Purchase Plan
    1988 Stock Plan
    1994 Key Executive Stock Plan
    Heska Corporation 2003 Equity Incentive Plan
    1997 Employee Stock Purchase Plan of Heska Corporation, As Amended and Restated
    Stock Incentive Plan of Heska Corporation (f/k/a the Amended and Restated 1997 Stock Incentive Plan of Heska Corporation)
    Heska Corporation 2020 Employee Stock Purchase Plan
    Heska Corporation Equity Incentive Plan
    (Full Title of the Plans)

    Kevin S. Wilson
    Chief Executive Officer and President
    Heska Corporation
    3760 Rocky Mountain Avenue
    Loveland, Colorado 80538
    (Name and Address, including Zip Code, of Agent for Service)

    Copy to:
    Krista Hanvey
    Gibson, Dunn & Crutcher LLP
    2001 Ross Avenue, Suite 2100
    Dallas, Texas 75201
    (214) 698-3100


    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☒
    Accelerated filer
    ☐
           
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
           
       
    Emerging growth company
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE
    DEREGISTRATION OF SECURITIES

    These post-effective amendments (the “Post-Effective Amendments”) relate to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”) previously filed by Heska Corporation, a Delaware corporation (“Heska”), with the U.S. Securities and Exchange Commission (the “SEC”):


    •
    Registration Statement on Form S-8 (File No. 333-30951), originally filed with the SEC on July 9, 1997, registering 250,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the Heska Corporation Employee Stock Purchase Plan.

    •
    Registration Statement on Form S-8 (File No. 333-34111), originally filed with the SEC on August 21, 1997, registering 1,785,869 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1988 Stock Plan, 125,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1994 Key Executive Stock Plan, and 1,612,461 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-47129), originally filed with the SEC on February 27, 1998, registering 942,701 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-72155), originally filed with the SEC on February 11, 1999, registering 1,322,921 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-38138), originally filed with the SEC on May 31, 2000, registering 1,500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-39448), originally filed with the SEC on June 16, 2000, registering 500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the Heska Corporation Employee Stock Purchase Plan.

    •
    Registration Statement on Form S-8 (File No. 333-55112), originally filed with the SEC on February 7, 2001, registering 1,500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-82096), originally filed with the SEC on February 4, 2002, registering 1,500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-89738), originally filed with the SEC on June 4, 2002, registering 1,000,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the Heska Corporation Employee Stock Purchase Plan.

    •
    Registration Statement on Form S-8 (File No. 333-102871), originally filed with the SEC on January 31, 2003, registering 1,500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-106679), originally filed with the SEC on June 30, 2003, registering 2,390,500 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the Heska Corporation 2003 Equity Incentive Plan.

    •
    Registration Statement on Form S-8 (File No. 333-112701), originally filed with the SEC on February 11, 2004, registering 1,500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-115995), originally filed with the SEC on May 28, 2004, registering 1,000,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the Heska Corporation Employee Stock Purchase Plan.

    •
    Registration Statement on Form S-8 (File No. 333-123196), originally filed with the SEC on March 8, 2005, registering 1,500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-132916), originally filed with the SEC on April 3, 2006, registering 1,500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-141737), originally filed with the SEC on April 2, 2007, registering 1,500,000 shares of Heska’s common stock, par value $0.001 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-194120), originally filed with the SEC on February 25, 2014, registering 410,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-194122), originally filed with the SEC on February 25, 2014, registering 100,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the Heska Corporation Employee Stock Purchase Plan.

    •
    Registration Statement on Form S-8 (File No. 333-195734), originally filed with the SEC on May 6, 2014, registering 130,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-204036), originally filed with the SEC on May 11, 2015, registering 75,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the 1997 Employee Stock Purchase Plan, As Amended and Restated.

    •
    Registration Statement on Form S-8 (File No. 333-211567), originally filed with the SEC on May 25, 2016, registering 500,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the Amended and Restated 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-225112), originally filed with the SEC on May 22, 2018, registering 250,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the Amended and Restated 1997 Stock Incentive Plan of Heska Corporation.

    •
    Registration Statement on Form S-8 (File No. 333-238006), originally filed with the SEC on May 5, 2020, registering 300,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the Stock Incentive Plan of Heska Corporation (f/k/a the Amended and Restated 1997 Stock Incentive Plan of Heska Corporation).

    •
    Registration Statement on Form S-8 (File No. 333-238008), originally filed with the SEC on May 5, 2020, registering 200,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the Heska Corporation 2020 Employee Stock Purchase Plan.

    •
    Registration Statement on Form S-8 (File No. 333-255803), originally filed with the SEC on May 6, 2021, registering 250,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the Heska Corporation Equity Incentive Plan.

    •
    Registration Statement on Form S-8 (File No. 333-266637), originally filed with the SEC on August 8, 2022, registering 130,000 shares of Heska’s common stock, par value $0.01 per share, issuable in connection with the Heska Corporation Equity Incentive Plan.

    These Post-Effective Amendments are being filed in connection with the closing on June 13, 2023 of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of March 31, 2023, by and among Heska, Antech Diagnostics, Inc. (“Acquiror”), Helsinki Merger Sub LLC (“Merger Sub”) and, solely for purpose of Section 9.15 of the Merger Agreement, Mars, Incorporated (“Parent”). On June 13, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into Heska (the “Merger”), with Heska surviving the Merger and continuing as a wholly-owned indirect subsidiary of Parent. As a result of the Merger, Heska has terminated all offerings of Heska’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made by Heska in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, Heska hereby removes from registration all such securities of Heska registered pursuant to the Registration Statements that remain unsold and any plan interests that are unissued as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Loveland, State of Colorado, on June 13, 2023. No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     
    HESKA CORPORATION
       
     
    By:
    /s/ Kevin Wilson
     
     
    Name:
    Kevin Wilson
     
    Title:
    Chief Executive Officer and President



    Get the next $HSKA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSKA

    DatePrice TargetRatingAnalyst
    1/6/2023$58.00Equal-Weight → Underweight
    Morgan Stanley
    3/1/2022$190.00 → $161.00Equal-Weight
    Morgan Stanley
    2/23/2022$300.00 → $250.00Overweight
    JP Morgan
    1/6/2022$210.00Overweight
    Piper Sandler
    11/18/2021$190.00Equal-Weight
    Morgan Stanley
    8/4/2021$240.00 → $305.00Overweight
    Piper Sandler
    7/12/2021$280.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $HSKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Heska Corp downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Heska Corp from Equal-Weight to Underweight and set a new price target of $58.00

      1/6/23 8:09:57 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morgan Stanley reiterated coverage on Heska with a new price target

      Morgan Stanley reiterated coverage of Heska with a rating of Equal-Weight and set a new price target of $161.00 from $190.00 previously

      3/1/22 9:56:21 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • JP Morgan reiterated coverage on Heska with a new price target

      JP Morgan reiterated coverage of Heska with a rating of Overweight and set a new price target of $250.00 from $300.00 previously

      2/23/22 8:14:03 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Financials

    Live finance-specific insights

    See more
    • Heska Corporation Reports Fourth Quarter and Full Year 2022 Results

      Full Year Sales $257.3 Million, Full Year Gross Margin Up 150 Basis Points to 43.2% Full Year North America Lab Consumables Sales Up 8.7%, Total Active Subscriptions Up 18% LOVELAND, Colo., Feb. 28, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results in two segments (North America and International) for its fourth quarter and full year ended December 31, 2022. Fourth Quarter and Full Year 2022 and Year Over Year ("YOY") Metrics $ in mi

      2/28/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Fourth Quarter and Full Year 2022 Financial Results and Earnings Call Scheduled for February 28, 2023

      LOVELAND, Colo., Feb. 8, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ:HSKA, ", Heska", or the ", Company", ))), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its fourth quarter and full year 2022 financial performance in a press release before the market opens on Tuesday, February 28, 2023. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results. To access the conference call: From within the United States, please dial 1-877-41-6152From outside of the United States, please dial 1-201-389-

      2/8/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Heska Corporation Completes Acquisition of LightDeck Diagnostics

      LOVELAND, Colo., Jan. 3, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty products and solutions, today announced the completion of acquisition of 100% of the shares of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics ("LightDeck"), a pioneer in planar waveguide fluorescence immunoassay diagnostics with strong manufacturing capabilities and research and development expertise (the "Acquisition").  The Acquisition, which was first announced on September 12, 2022, represent

      1/3/23 8:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    SEC Filings

    See more
    • SEC Form 15-12G filed by Heska Corporation

      15-12G - HESKA CORP (0001038133) (Filer)

      6/23/23 6:01:38 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Heska Corporation

      EFFECT - HESKA CORP (0001038133) (Filer)

      6/14/23 12:15:09 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Heska Corporation

      EFFECT - HESKA CORP (0001038133) (Filer)

      6/14/23 12:15:13 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Leadership Updates

    Live Leadership Updates

    See more
    • Heska Corporation Elects Dr. Joachim Hasenmaier to Board of Directors

      LOVELAND, Colo., Jan. 12, 2021 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, appointed Dr. Joachim Hasenmaier, the former head of Boehringer Ingelheim Animal Health, to the Company's Board of Directors, effective January 11, 2021. Dr. Joachim Hasenmaier most recently served as a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer healthcare businesses. Previously, as head of animal health of Boehringer Ingelheim, Dr. Hasenmaier led the rapid growth and expansion

      1/12/21 4:30:00 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Maples Sharon J.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:54 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Eyl Steven M.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:55 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Hasenmaier Joachim A.

      4 - HESKA CORP (0001038133) (Issuer)

      6/14/23 6:27:56 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      4/10/23 2:50:12 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      2/14/23 4:07:17 PM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Heska Corporation (Amendment)

      SC 13G/A - HESKA CORP (0001038133) (Subject)

      2/10/23 10:12:43 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $HSKA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bee Vaccine Pioneer Dalan Secures $4.5M to Fuel Global Expansion and Product Development

      Key Points: $4.5 million in Series Seed 3 funding, led by Prime Movers Lab with participation from At One Ventures, bringing the company's total funding to $10 million. The funding will accelerate Dalan's product pipeline and facilitate its global expansion, aiming to protect the health of honeybees and secure the global food supply. Dalan Animal Health, Inc. ("Dalan"), a pioneering biotech company in insect health, today announced the successful closure of a $4.5 million Series Seed 3 funding round. The round was led by Prime Movers Lab with participation from At One Ventures, bringing Dalan's total funding to $10 million. The additional funding will enable Dalan to expedite its

      6/27/23 9:00:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • eXp World Holdings & Privia Health Group Set to Join S&P SmallCap 600

      NEW YORK, June 7, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, June 14: eXp World Holdings Inc. (NASD: EXPI) will replace Heska Corp. (NASD: HSKA). Mars Inc. is acquiring Heska in a deal expected to be completed soon pending final conditions.Privia Health Group Inc. (NASD: PRVA) will replace Ruth's Hospitality Group Inc. (NASD: RUTH). S&P 500 constituent Darden Restaurants Inc. (NYSE:DRI) is acquiring Ruth's Hospitality Group in a deal expected to be completed soon pending final conditions.Following is a summary of the changes that will take place prior to the open of trading on the

      6/7/23 6:37:00 PM ET
      $DRI
      $EXPI
      $HSKA
      $PRVA
      Restaurants
      Consumer Discretionary
      Real Estate
      Finance
    • Dalan Animal Health Ships First Honey Bee Vaccine to Tauzer Apiaries, Potentially Protecting 25 Million Bees.

      Dalan Animal Health, Inc. ("Dalan"), the biotech company pioneering insect health with the world's first honey bee vaccine, is proud to announce its first product shipment to a commercial beekeeper. The shipment is for Trevor Tauzer of Tauzer Apiaries in California and contains 500 doses, potentially protecting 25 million bees at an average of 50,000 bees per hive. This milestone follows the U.S. Department of Agriculture (USDA) granting a conditional license to Dalan's first-in-class honeybee vaccine earlier this year. The vaccine is indicated to protect honeybees against the devastating American Foulbrood disease caused by the bacteria Paenibacillus larvae. Honeybees are a critical co

      5/23/23 7:20:00 AM ET
      $HSKA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care